BCR and posterior cortical atrophy: At the time of diagnostic imaging, patients were in the following clinical settings: primary PCa staging (3/14), mCRPC (4/14), biochemical recurrence (BCR) (3/14), primary staging + BCR (1/14), hormone-sensitive prostate cancer (HSPC) + CRPC (1/14), early PSA progression on androgen-deprivation therapy (ADT) (1/14), and PCa (1/14).